Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 9/20 | 0.44 |
| ▸ | HCRTR2 | O43614 | 7/20 | 0.44 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4292999 | 0.96 | HCRTR1 (0.45) | HCRTR1HCRTR2CHEK2ALDH1A1MEN1 | |
| SCHEMBL13705475 | 0.95 | HCRTR1 (0.42) | HCRTR1HCRTR2CHEK2ALDH1A1MEN1 | |
| SCHEMBL13819440 | 0.95 | HCRTR1 (0.42) | HCRTR1HCRTR2CHEK2ALDH1A1MEN1 | |
| SCHEMBL13705472 | 0.95 | HCRTR1 (0.41) | HCRTR1HCRTR2CHEK2CHRM3 | |
| SCHEMBL13705465 | 0.92 | HCRTR1 (0.41) | HCRTR1HCRTR2CHEK2ALDH1A1MEN1 | |
| SCHEMBL13705467 | 0.92 | HCRTR1 (0.41) | HCRTR1HCRTR2CHEK2ALDH1A1MEN1 | |
| SCHEMBL13705466 | 0.92 | HCRTR1 (0.41) | HCRTR1HCRTR2CHEK2MEN1KMT2A | |
| SCHEMBL4293415 | 0.92 | HCRTR1 (0.44) | HCRTR1HCRTR2CHEK2ALDH1A1 | |
| SCHEMBL8127245 | 0.92 | HCRTR1 (0.41) | HCRTR1HCRTR2CHEK2CHRM3 | |
| SCHEMBL13705420 | 0.92 | HCRTR1 (0.41) | HCRTR1HCRTR2CHEK2CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227560-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20090227560-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20090156612-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
| US-20090156612-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156612-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | HCRTR1 3147/4885HCRTR2 3136/4885CHEK2 3289/4885 |
| US-20090227560-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | HCRTR1 3147/4885HCRTR2 3136/4885CHEK2 3289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.